Skip to navigation Skip to content

Ofatumumab Versus Teriflunomide

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 900
Medication: Ofatumumab Versus Teriflunomide
Location: Texas
Institutions: Clinical Trial Network
7080 southwest fwy, Houston, TX 77074 Contact Information
Michelle Espiritu
281-533-5000
mespiritu@ctntexas.com

Funding:

Novartis

Description

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis.

Share


Your input is important!

We believe that people affected by MS live better lives when they're connected.  To help us provide you with the best resources, support and information, please provide your feedback in a short survey.
Take the survey